OncoMatch/Colorectal Cancer (CRC)/MMR / MSI-H
Colorectal Cancer (CRC)MMR / MSI-H Clinical Trials
Mismatch repair deficiency (dMMR), detected by IHC loss of any MMR protein or by PCR/NGS for microsatellite instability-high (MSI-H), defines an immunotherapy-responsive subgroup in approximately 4% of metastatic CRC. Pembrolizumab is first-line standard for dMMR/MSI-H metastatic CRC; nivolumab ± ipilimumab provides an alternative. Trials study neoadjuvant immunotherapy for early-stage dMMR CRC and combinations to address primary resistance.
Top recruiting MMR / MSI-H Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 44 trials matched to your profile →
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Canadian Cancer Trials Group
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Sun Yat-sen University
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Sir Run Run Shaw Hospital
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Gruppo Oncologico del Nord-Ovest